MY127938A - Combinatin therapy for treatment of partial responders or refractory depression - Google Patents

Combinatin therapy for treatment of partial responders or refractory depression

Info

Publication number
MY127938A
MY127938A MYPI99002017A MYPI9902017A MY127938A MY 127938 A MY127938 A MY 127938A MY PI99002017 A MYPI99002017 A MY PI99002017A MY PI9902017 A MYPI9902017 A MY PI9902017A MY 127938 A MY127938 A MY 127938A
Authority
MY
Malaysia
Prior art keywords
treatment
refractory depression
partial responders
activity
compound
Prior art date
Application number
MYPI99002017A
Other languages
English (en)
Inventor
Gary Dennis Tollefson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MY127938A publication Critical patent/MY127938A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compositions Of Oxide Ceramics (AREA)
MYPI99002017A 1998-05-22 1999-05-21 Combinatin therapy for treatment of partial responders or refractory depression MY127938A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8644498P 1998-05-22 1998-05-22

Publications (1)

Publication Number Publication Date
MY127938A true MY127938A (en) 2007-01-31

Family

ID=22198612

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI99002017A MY127938A (en) 1998-05-22 1999-05-21 Combinatin therapy for treatment of partial responders or refractory depression

Country Status (24)

Country Link
EP (1) EP0958824A3 (cs)
JP (1) JP2002516282A (cs)
KR (1) KR20010043730A (cs)
CN (1) CN1154496C (cs)
AU (1) AU761510B2 (cs)
BR (1) BR9911049A (cs)
CA (1) CA2332814C (cs)
CZ (1) CZ20004279A3 (cs)
EA (1) EA004539B1 (cs)
HK (1) HK1040055B (cs)
HR (1) HRP20000797A2 (cs)
HU (1) HUP0101901A3 (cs)
ID (1) ID26861A (cs)
IL (1) IL139592A (cs)
MY (1) MY127938A (cs)
NO (1) NO20005885L (cs)
NZ (1) NZ507980A (cs)
PL (1) PL344331A1 (cs)
SK (1) SK17512000A3 (cs)
TR (1) TR200003443T2 (cs)
TW (1) TWI226829B (cs)
UA (1) UA78181C2 (cs)
WO (1) WO1999061027A1 (cs)
ZA (1) ZA200006815B (cs)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2352611A1 (en) * 1998-11-23 2000-06-02 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
SI1237553T1 (sl) * 1999-12-06 2006-06-30 Lundbeck & Co As H Kombinacija inhibitorja ponovnega navzema serotonina in antagonista 5-ht 2c?, inverznega agonista ali delnega agonista
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
MXPA03006003A (es) * 2001-01-02 2005-09-08 Upjohn Co Nuevas combinaciones de farmacos.
EP1551393A4 (en) * 2002-07-30 2010-06-16 Peter Migaly COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS
GB0229583D0 (en) * 2002-12-19 2003-01-22 Cipla Ltd A process for preparing duloxetine and intermediates for use therein
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
WO2004060374A1 (en) 2002-12-27 2004-07-22 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
MXPA06002504A (es) * 2003-09-04 2006-06-20 Lundbeck & Co As H Combinacion de un inhibidor de recaptacion de serotonina y loxapina.
SG146683A1 (en) 2003-09-17 2008-10-30 Janssen Pharmaceutica Nv Fused heterocyclic compounds as serotonin receptor modulators
EP1713486A4 (en) * 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
WO2005056056A2 (en) * 2003-12-15 2005-06-23 H. Lundbeck A/S The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
EP2275096A3 (en) * 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
MY150647A (en) 2006-06-16 2014-02-14 Lundbeck & Co As H 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
CA2677623C (en) * 2007-02-09 2015-04-07 Alphapharm Pty Ltd A dosage form containing two or more active pharmaceutical ingredients in different physical forms
TWI432194B (zh) * 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN105769875A (zh) * 2014-12-22 2016-07-20 扬子江药业集团上海海尼药业有限公司 复方奥氮平盐酸氟西汀胶囊的制备方法
CN108938645A (zh) * 2018-08-24 2018-12-07 山西医科大学第医院 一种抗精神病药物组合物
CN111084778B (zh) * 2019-12-31 2022-06-24 北京鑫开元医药科技有限公司 一种奥氮平盐酸氟西汀胶囊及其制备方法
CN114569566A (zh) * 2020-12-02 2022-06-03 四川科瑞德制药股份有限公司 一种盐酸米那普仑制剂的制备方法
ES3054324B2 (es) * 2024-07-12 2026-08-10 Univ De Malaga Galanina (1-15) y Fluoxetina en el tratamiento de la depresión resistente al tratamiento

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8072691A (en) * 1990-06-28 1992-01-23 Beecham Group Plc Pharmaceutical preparations
FR2716680B1 (fr) * 1994-02-25 1996-04-05 Adir Nouveaux dérivés de benzodioxane, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
WO1997033577A1 (en) * 1996-03-11 1997-09-18 Eli Lilly And Company Method for treating bipolar disorder
PL187926B1 (pl) * 1996-03-25 2004-11-30 Lilly Co Eli Kompozycja farmaceutyczna do leczenia bólu
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses

Also Published As

Publication number Publication date
IL139592A (en) 2005-08-31
ID26861A (id) 2001-02-15
WO1999061027A1 (en) 1999-12-02
CN1154496C (zh) 2004-06-23
HUP0101901A2 (hu) 2001-11-28
KR20010043730A (ko) 2001-05-25
JP2002516282A (ja) 2002-06-04
SK17512000A3 (sk) 2002-02-05
AU4008699A (en) 1999-12-13
CZ20004279A3 (cs) 2001-09-12
NZ507980A (en) 2003-10-31
AU761510B2 (en) 2003-06-05
PL344331A1 (en) 2001-11-05
HUP0101901A3 (en) 2002-06-28
CN1311681A (zh) 2001-09-05
HK1040055B (zh) 2005-04-01
NO20005885L (no) 2001-01-17
NO20005885D0 (no) 2000-11-21
HRP20000797A2 (en) 2001-10-31
CA2332814C (en) 2008-11-04
EP0958824A3 (en) 1999-12-01
HK1040055A1 (en) 2002-05-24
IL139592A0 (en) 2002-02-10
UA78181C2 (en) 2007-03-15
EA200001218A1 (ru) 2001-06-25
TWI226829B (en) 2005-01-21
EP0958824A2 (en) 1999-11-24
ZA200006815B (en) 2002-01-14
CA2332814A1 (en) 1999-12-02
TR200003443T2 (tr) 2001-03-21
BR9911049A (pt) 2001-02-06
EA004539B1 (ru) 2004-06-24

Similar Documents

Publication Publication Date Title
CA2332814A1 (en) Combination therapy for treatment of refractory depression
TR200003525T2 (tr) Bipolar bozuklukların tedavisi için kombinasyon terapisi
IL188249A0 (en) Cephalosporin related compounds for use in therapy
AP1498A (en) Inhibitors of impdh enzyme.
HUP0203304A2 (hu) Prosztatarák megelőzésére szolgáló kemoterápiás módszer és készítmény
ES2191152T3 (es) Terapia combinada para el tratamiento de psicosis.
ATE372341T1 (de) Inhibitoren von mitotischem kinesin
MXPA05005107A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
ATE424388T1 (de) Mitotische kinesinhemmer
ATE447577T1 (de) Mitotische kinesin-hemmer
DE69816280D1 (de) Inhibitoren des impdh-enzyms
WO2003073999A3 (en) Pini-modulating compounds and methods of use thereof
ATE356804T1 (de) Inhibitoren von mitotischem kinesin
WO2003074550A3 (en) Pin1-modulating compounds and methods of use thereof
PL1742644T3 (pl) Kompozycja terapeutyczna zawierająca co najmniej jedną pochodną pirolobenzodiazepiny i fludarabiny
AU2002327180A1 (en) Detection and therapy of vulnerable plaque with photodynamic compounds
UA70925C2 (uk) Спосіб лікування естрогенстимульованого раку
EA199800667A1 (ru) Новые фенантридины
MY137766A (en) Exemestane as chemopreventing agent
DE60127537D1 (de) VERWENDUNG VON 2-(4-ETHOXY-PHENYL)-3-(4-METHANESULFONYL-PHENYL)-PYRAZOLOÄ1,5-bÜPYRIDAZINE ZUR BEHANDLUNG VON NICHTULZERATIVER DYSPEPSIE
ES2163795T3 (es) Composicion farmaceutica contra los tumores e infecciones por papilomavirus.
ATE443044T1 (de) Tace inhibitoren
DE602004028493D1 (de) Isochinolinon-kaliumkanalinhibitoren
WO2004047757A3 (en) Diagnosing and treating hematopoietic cancers
GEP20104888B (en) Use of carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders